Irvine Scientific Expands R&D Capabilities in Southern California
Irvine Scientific (Santa Ana, CA) today announced the expansion of its Orange County, CA, offices and laboratories, with the addition of a 40,000 square foot purpose-built R&D center at Irvine, CA. It is reported that new building will contain other departments that currently reside within its southern California-based headquarters, enabling the company to expand other capabilities, such as media customization for customers. Along with the facilities in Santa Ana, the new facility increases the total space occupied by Irvine Scientific in Orange County to over 140,000 square feet. For more information visit www.irvinesci.com
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
